Pfizer's medicine candidate tanezumab is the only new medicine that the European Committee for Medicinal Products for Human Use (CMPH) is refusing to approve. This is clear from the highlights publicized after the committee's September meeting.
Tanezumab, also known as Raylumis, was intended as a treatment for pains associated with osteoarthritis, a form of arthritis, and is currently being evaluated by the US Food and Drug Administration (FDA), however in March of this year, an FDA advisory committee also voted against a recommendation of approval – 19 people against one.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Carb-X secures USD 370m in fight against antibiotic resistance
International antibiotic alliance Carb-X has received commitments of up to USD 370m to accelerate the development of new antibiotics to combat a future shortage. The news is welcomed by several players on the AMR field.
Former Ambu CEO's equity investments end in USD 2m losses
Juan Jose Gonzalez, who was the CEO of medtech firm Ambu until very recently, has lost just over DKK 16m (USD 2.3m) before taxes on his share purchases.
Jesper Høiland retires as chief commercial officer of Ascendis Pharma
Former executive vice president of Novo Nordisk, US, Jesper Høiland has decided to step down from his role as global chief commercial officer at Ascendis Pharma.
ALK finds replacement for long-time North America lead
Jorge Alderete, ALK’s president in North America, is leaving the firm after 23 years. He will be replaced by Hans Lindeberg, ALK’s current head of the Nordic region.
Monkeypox vaccine attracts interest for Bavarian as virus spreads
Bavarian, which signed a supply contract with an unnamed European country last week, reports it is in dialog with several countries, some yet to be affected, concerning the firm’s monkeypox vaccine.
Industrial Designer- Design Engineer 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Quality System Manager 
IRT Manager, Clinical Drug Supply 
Communications Consultant 
Clinical Project Manager 
Production Director 
(Senior) Drug Substance Specialist 
2 Sales Representatives and Product Specialists 
Biomarker Operations Lead 
Key Account Manager, Europe and Asia 
Nordic Medical Affairs Manager 
Senior IT Network Engineer 
Director Global Engineering 
CMO Operations Specialist - screening & selection of CMO/CDMO’s